Key Points
- Director Josef Parvizi sold 25,000 shares on December 15 at an average price of $21.49 for $537,250, cutting his position by 3.13% to 772,652 shares (he also sold 25,000 shares on December 8 at $20.26).
- Stock and fundamentals: CeriBell shares recently traded near $21.62, the company has a market cap of about $802M, a negative trailing P/E, and a one‑year range of $10.01–$28.23.
- Analyst and earnings context: CeriBell beat recent EPS expectations (reported -$0.37 vs. -$0.43 consensus) but has negative margins; analysts rate it a "Moderate Buy" with an average target of $24.67.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) Director Josef Parvizi sold 25,000 shares of the stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $21.49, for a total value of $537,250.00. Following the transaction, the director directly owned 772,652 shares of the company's stock, valued at $16,604,291.48. The trade was a 3.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Josef Parvizi also recently made the following trade(s):
- On Monday, December 8th, Josef Parvizi sold 25,000 shares of CeriBell stock. The shares were sold at an average price of $20.26, for a total value of $506,500.00.
CeriBell Price Performance
Shares of CeriBell stock traded up $0.03 during trading hours on Thursday, reaching $21.62. 5,558 shares of the company's stock were exchanged, compared to its average volume of 316,774. The business has a fifty day moving average of $14.90 and a two-hundred day moving average of $14.61. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $801.92 million, a P/E ratio of -14.30 and a beta of 1.35. CeriBell, Inc. has a 1 year low of $10.01 and a 1 year high of $28.23.
CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.06. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. The company had revenue of $22.59 million during the quarter, compared to analysts' expectations of $21.78 million. As a group, research analysts predict that CeriBell, Inc. will post -2.46 earnings per share for the current fiscal year.
Hedge Funds Weigh In On CeriBell
Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in shares of CeriBell by 11.1% in the third quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company's stock worth $16,935,000 after buying an additional 147,013 shares during the last quarter. Yu Fan raised its stake in shares of CeriBell by 10.7% in the 2nd quarter. Yu Fan now owns 1,353,166 shares of the company's stock worth $25,345,000 after buying an additional 130,964 shares in the last quarter. Novo Holdings A S boosted its holdings in CeriBell by 2.3% during the second quarter. Novo Holdings A S now owns 900,000 shares of the company's stock worth $16,857,000 after buying an additional 20,000 shares in the last quarter. TimesSquare Capital Management LLC increased its stake in CeriBell by 2.6% in the 3rd quarter. TimesSquare Capital Management LLC now owns 817,645 shares of the company's stock worth $9,395,000 after purchasing an additional 20,700 shares in the last quarter. Finally, Millennium Management LLC raised its stake in CeriBell by 41.8% during the 3rd quarter. Millennium Management LLC now owns 666,448 shares of the company's stock valued at $7,657,000 after purchasing an additional 196,299 shares during the period.
Analyst Ratings Changes
Several equities analysts have weighed in on the stock. Cowen reiterated a "buy" rating on shares of CeriBell in a report on Tuesday, December 9th. JPMorgan Chase & Co. reduced their price target on shares of CeriBell from $21.00 to $17.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 5th. Weiss Ratings restated a "sell (e+)" rating on shares of CeriBell in a research note on Wednesday, October 8th. BTIG Research reissued a "buy" rating and set a $30.00 target price on shares of CeriBell in a research report on Monday. Finally, Canaccord Genuity Group boosted their target price on CeriBell from $29.00 to $30.00 and gave the company a "buy" rating in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, CeriBell has an average rating of "Moderate Buy" and an average target price of $24.67.
View Our Latest Stock Report on CeriBell
About CeriBell
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
